Suzhou Connect Biopharmaceuticals

Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation

placeSuzhou, Jiangsu, China calendar_todayFounded 2012 groups100 employees language connectbiopharm.com

Investor mix

12 investors on record; lead investors include RA Capital Management, Qiming Venture Partners, Advantech Capital, Cowin Capital; 1 has since exited.

Investor typeCountShare
Venture capital867%
Private equity217%
Other / undisclosed217%
Coming soon